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ABSTRACT
Medicine is moving from reacting to a disease to prepare personalised and precision paths to well
being. The complex and multi level pathophysiological patterns of most diseases require a systemic
medicine approach and are challenging current medical therapies. Computational medicine is a
vibrant interdisciplinary field that could help moving from an organ-centered to a process-oriented or
systemic medicine data analysis. The resulting Computational patient may require an international
interdisciplinary effort, probably of larger scientific and technological interdisciplinarity than the
human genome sequencing. When deployed, it will have a profound impact on how healthcare is
delivered to patients. Here we present a Computational patient model that integrates, refine and
extend recent specific mechanistic or phenomenological models of cardiovascular, RAS and diabetic
processes. Our aim is twofold: analyse the modularity and composability of the models-building
blocks of the Computational patient and to study the dynamical properties of well-being and disease
states in a broader functional context. We present results from a number of experiments among
which we characterise the dynamical impact of covid-19 and T2D diabetes on cardiovascular and
inflammation conditions. We tested these experiments under exercise and meals and drug regimen.
We report results showing the striking importance of transient dynamical responses to acute state
conditions and we provide guidelines for system design principle of the inter-relationship between
modules and components for systemic medicine. Finally this initial Computational Patient can be
used as a toolbox for further modifications and extensions.
Keywords Computational Patient · Computational Medicine · Systems medicine · Covid · T2D Diabete · Cardiovascular
model · Blood Pressure model
1 Introduction
Computational medicine is increasingly effective to understand and predict complex physiological and pathological
conditions in scenarios of single organ disease to comorbidities. Important aspects of computational medicine are
mechanistic and phenomenological models. When we formulate hypotheses on the mechanisms (usually involving
molecules) underlying the behaviour of the various endpoints of a process, we could build a mechanistic model; when
we formulate hypotheses based on the empirical observations of a phenomenon, we could build a phenomenological
model. Most models are actually a combination of the two and there are certainly overlaps between phenomenological
modeling, statistical and machine learning. Mechanistic and phenomenological modeling aim at reproducing the main
features of a real system with the minimum number of parameters and still providing explainability, interpretability
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and often causality. The objective is to gain a better understanding of how each of the different components of a
biomedical system contributes to the overall process, its emerging properties and the causality relation of the occurred
events. A mechanistic and phenomenological model could be formulated using ordinary or partial differential equations
[1], stochastic processes [2], logic [3] or in terms of a tailor-made syntax which could facilitate formal analysis and
verification [4, 5]. The dedicated modeler may introduce a series of models of a process at different scales, from
the molecular level to the whole body level, or describing processes occurring in different organs under the same
disease conditions. Although there is growing awareness of long range communications in the body - for instance
the communicome [6] or the gut-brain axis [7], the integration of various models in order to capture the behavior at
systems medicine level has not been pursued so much. Examples of such multi level communication are given by the
extensive network of comorbidities. Comorbidity is the term used to address diseases, often chronic ones, co-occurring
in the same individual. An importance challenge is the homogenisation of models across multiple spatial and time
scales, which requires cell-level models to be systematically scaled up to the tissue/organ level, and related asymptotic
techniques for the analysis of multiple timescale problems, such as those arising in processes communications. The
cardiovascular system is usually described using a cardio-centric view. The heart is consider as the only pump in the
system. Other pumps are actually the skeletal muscle which returns blood from the periphery to the central circulation.
Another pump is embedded in the elastic arteries that use elastic properties to propel the blood forward. This system
is subtly coupled with the cardiovascular-associated nervous system and the blood pressure control which include
the regulated inputs from many other organs, most notably lungs, kidney and pancreas [8]. Therefore, the concept of
cardiovascular disease could be reformulated as a more complexly connected system and disease landscape, perhaps
inclusive of comorbidities, which could allow a better patient stratification and prognosis and consequently better drug
discovery.
In particular infectious diseases are good examples of the need of inter organ and inter process modeling approaches
as a pathogen’ s fitness may require colonising different body’s environments. A current example is given by the
COVID-19 pandemia. Diabetes is a frequent comorbidity; the Coronado study has shown that 29% of the people with
T2D infected with Covid-19 were intubated and 10.6% die in one week [9]. The mortality statistics shows that fighting
the COVID-19 pandemia requires a focus on comorbidities. Many of the older patients who become severely ill have
evidence of underlying illness such as cardiovascular disease, kidney disease, T2D or tumours [10]. They make the
largest percentage of patient who cannot breathe on their own because of severe pneumonia and acute respiratory
distress syndrome and require intubation: about a quarter of intubated coronavirus patients dies within the first few
weeks of treatment [11].
2 Objectives
The aim of this work is twofold. First, in Sec. 3 we propose a modular approach for the design of personalised
computational physiology systems. The complexity underlying multifactorial diseases requires the introduction of
multi-scale, extensible and adaptable models where modular principles are used to break organism complexity and
composable criteria to select, link and combine different components in a hierarchical fashion. In order to show the
advantages of such modeling approach, in Sec. 6 we illustrate a concrete example where personalised comorbid
conditions’ dynamics can be modeled and analysed using our framework. We focus on developing an integrated
computational system modeling ripple effects of comorbidities on blood pressure regulation. To this end, in Sec. 4
we revised the physiological background required to understand the main underlying biological processes involved
in this mechanism. Building upon previous studies, we devise a customisable Computational patient in the form of
a computational tool composed of extended versions of three publicly available mathematical models describing the
circulatory system [12], type-2 diabetes [13], and renin-angiotensin system (RAS) [14], one of the main pathways
regulating inflammatory response and blood pressure. Respiratory failure is a key feature of severe Covid-19 and a
critical driver of mortality; 10.6% of all diabetic patients hospitalised die within one week. Hence, in Sec. 5 we propose
a set of equations modeling the impact of type 2 diabetes on blood vessels’ stiffness and the influence of additional
external factors which can be personalised according to patient’s characteristics and lifestyle habits. We introduce
a variety of such elements describing the repercussions on blood pressures caused by ageing, type-2 diabetes, viral
infections like COVID19, ACE inhibitor treatments, meals, and physical exercise.
3 Computational tool
3.1 From integration to modularity and composability
In the last decades, the interest and the scientific effort in developing integrated quantitative and descriptive compu-
tational systems modeling physiological dynamics has rapidly grown. By 1997 the Physiome Project [15] and the
EuroPhysiome Initiative [16] have actively devised and organised rich collections of mathematical models describing
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the functional behavior of components of living organisms, such as organs, cell systems, biochemical reactions, or
endocrine systems. Such modular approach has been primarily used to reduce complexity by deconvolving the human
physiome into elementary subunits. Indeed, each computational module can be seen as a standalone biological entity
describing one of the structures, processes, or pathways of the whole organism. Yet, modeling physiological interactions,
multi-scale signalling, and comorbidities requires the combination of multiple components to build more sophisticated
computational systems. Several approaches have been proposed where different mathematical models have been
integrated into a single system in order to describe synergistic effects and emerging phenomena [12]. Despite being
widely used and accepted, such system design paradigm often requires an overwhelming amount of work in merging
multiple systems together, and in tuning and validating the integrated model. Besides, technological advances in
computer science in the last twenty years have dramatically changed coding languages and paradigms. Hence, different
research groups have developed their computational systems on many different coding platforms, frameworks, and
libraries, including general-purpose languages like MatLab, Java, Python, C, but also special-purpose ones like JSim.
The variety of implementation platforms combined with the mathematical effort required to merge many different
systems is in conflict with the urgent need of user-friendly, extensible, and adaptable system design paradigms where
components can be selected and assembled in various combinations to satisfy specific requirements. Personalised
medicine requires the introduction of novel system design paradigms where modules break organism complexity and
composable criteria are used to select and combine different components. Instead of merging, tuning, and validating
the whole integrated system, each module could be tuned and validated independently. Composable criteria may
allow researchers to primarily focus on multi-scale signalling between modules. Tuning and validation may apply
just on inter-module signals which will make the overall system independent on module-specific implementation
characteristics.
healthyneighbourhood
trajectories
death
PHASE SPACE
PARAMETER SPACE
module A
module B
module C
(A)
(B)
(C)
Figure 1: In modular systems several modules can be used independently to model physiological processes, disregarding
their mutual relationships (A). The selection and combination of different components in a hierarchical fashion by
means of composable criteria allows a better exploration of the parameter space (B). The actual interpenetration of
multiple systems can be achieved by modeling the dynamics of their mutual relationships providing further information
on the underlying phenomena (C). Such deeper exploration of the parameter space enhances the evaluation of initial
conditions and trajectories in the phase space (right).
Figure design inspired by [17].
3.2 Module design and personalisation
In order to move towards this modern system design, each module can be seen as a black box processing signals coming
from other modules and combining them with external subject-specific parameters in order to provide a set of responses
(see Fig. 2). Subject-specific parameters may be derived from on-line clinically relevant measures, such as heart
pressure or insulin levels, or from patient’s medical records, such as morbidities, treatments, or clinical examinations.
Such elements can be used to personalise the module taking into account unique subject characteristics. Incoming
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signals from other components may impact some of the variables and parameters of the module, but cannot change its
architecture. Finally, the outputs provided by each module can be simultaneously used as inputs for other components
or tracked as clinically relevant latent variables.
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Figure 2: Modular paradigms are used to break organism complexity into simpler components which can be analysed
and modeled independently (left). Modules’ integration requires an overwhelming amount of work in merging one after
the other multiple systems together, and in tuning and validating the final model (top right). Composable criteria favor
a dynamic and adaptable selection of different components allowing researchers to primarily focus on modeling the
relationships between modules (bottom right).
Illustrations adapted from The Sourcebook of medical illustration [18].
3.3 Usage guidelines
The computational system has been designed in order to allow for three levels of user interaction. Computational
scientists and coders may take advantage of publicly available code by improving or forking the GitHub repository [19].
The repository structure has a modular design so that new packages can be included independently. Each new package
should correspond to a new mathematical model. Multiple packages can be combined together in order to generate
more complex computational systems. Medical practitioners and biologists with some Python experience may just
download the repository, reproduce the simulations on their computers, or modify some parameters. In order to make
the computational tool available for clinicians and practitioners without coding skills, the whole computational system
has been incorporated into a website with a graphical user interface. Users may profit from this user-friendly interaction
as the system can be customised in many different ways creating multiple scenarios by modifying several parameters,
including patient-specific characteristics and constants related to models’ interactions.
3.4 Numerical methods
All the necessary code for the experiments has been implemented in Python 3, relying upon open-source libraries.
The mathematical equations described in Sec. 5 form a set of ODE systems and algebraic equations that have been
sequentially solved using the LSODA integration method [20, 21] provided by the function solve_ivp included into the
scipy Python package [22]. All the experiments have been run on the same machine: Intel R© CoreTM i7-8750H 6-Core
Processor at 2.20 GHz equipped with 8 GiB RAM.
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4 Physiological background
4.1 The link between hypertension, oxygenation and blood pressure variability
Exposure to chronic hypoxia causes pulmonary hypertension and pulmonary vascular remodelling [23]. Covid results
in decreased oxygen that can result in impaired functioning of the heart and brain and cause difficulty with breathing (a
PaO2 reading below 80 mm Hg or a pulse ox (SpO2) below 95 percent is considered low). When the left side of the
heart cannot pump blood out to the body normally, blood backs up in the lungs and increases blood pressure there. The
covid19 virus can activate the blood clotting pathway. Studies have reported that 30% COVID-19 patients showed signs
of blood clots in their lungs which means that a blood clot that has traveled to the lung. One of the recommendations
is to give a low dose of heparin, which prevents clot formation or tissue plasminogen activator (tPA), which helps to
dissolve blood clots. High blood pressure can damage the arteries by making them less elastic, which decreases the
flow of blood and oxygen and leads to heart disease. The relationship between blood pressure and stroke recurrence
is controversial. Recent researches stress that both high mean value of blood pressure and blood pressure variability
(particularly long term) are important. Although some variation in blood pressure throughout the day is normal, higher
variation in blood pressure is associated with a higher risk of cardiovascular disease and all-cause mortality [24, 25]. In
young people here is a an increased blood supply response to hypoxia which could vanish in elderly with high blood
pressure. This compromised response may be caused by the high blood pressure-induced impairment in the function of
the blood vessels [26].
4.1.1 Arterial stiffness
Blood pressure variability and arterial stiffness independently predict cardiovascular risk [27, 28, 29, 30, 31]. Ageing
increases arterial stiffness and that increased arterial stiffness gives rise to increased blood pressure variability [32].
Arterial stiffness is a broad term used to describe loss of arterial compliance and changes in vessel wall properties.
Although arterial stiffness can be assessed using a variety of techniques, carotid–femoral pulse wave velocity is the
preferred measure. It has been shown that increased arterial stiffness is an early risk marker for developing type 2
diabetes [33], and a causal association between T2D and increased arterial stiffness has been proved on a large cohort of
patients [34, 35]: 1 standard deviation increase in T2D is associated with 6% higher risk in increased arterial stiffness;
see also [36]. Arterial stiffness is also related to Inflammageing which is a chronic low-grade inflammation that develops
with advanced age. It is believed to accelerate the process of biological ageing and to worsen many age-related diseases
[37, 38]. In particular inflammatory cytokines (which may be activated by angiotensinII) result in increased arterial
stiffness; on the contrary reductions in inflammation (for example due to anti-inflammatory cytokines), exercise reduce
arterial stiffness [39, 40].
4.2 The renin-angiotensin system and SARS-CoV-2
The renin-angiotensin system (RAS) is a hormone system regulating vasoconstriction and inflammatory response [41].
The key regulator of the RAS is the peptide hormone Angiotensin II (ANG-II) generated by the angiotensin-converting
enzyme (ACE) which cleaves the decapeptide Angiotensin I (ANG-I), or proangiotensin. ANG-II exerts its biological
functions through two G-protein-coupled receptors, the ANG-II receptor type 1 receptor (AT1R) and ANG-II receptor
type 2 receptor (AT2R), and the heptapeptide Angiotensin (1-7) (ANG-(1-7)) which binds and activates the G-protein-
coupled Mas receptor (MAS). ANG-(1-7) can be generated both by the angiotensin-converting enzime 2 (ACE2) from
ANG-II, or by the neutral endopeptidase enzyme (NEP) from ANG-I. The three G-protein-coupled receptors (AT1R,
AT2R, and MAS) are the main factors regulating blood pressure and systemic vascular resistance [42][43]. On one side,
AT1R stimulates vasoconstriction, hypertension, and inflammatory response. The effect of AT1R is counterbalanced by
AT2R and MAS, promoting vasodilation, hypotension, and vasoprotection. External factors impacting the RAS include:
glucose concentration, ACE inhibitor treatements, and viral infections binding to ACE2, such as SARS-CoV-2. The
glucose concentration has a direct impact both on AT1R and ACE activity. Hence, a high glucose concentration may
determine chronic hypertensive conditions. Therefore, hypertensive treatments usually include ACE inhibitor drugs
which are used to compensate the overproduction of ANG-II and AT1R [44]. Viral infections such as COVID19 may
also have a negative impact on RAS [45], as the virus binds to ACE2 in order to gain entry into the host cell, impairing
the activity of ACE2 in generating ANG-(1-7) by hydrolyzing ANG-II.
5 Mathematical model of diabetic Computational patients
In this section we describe the set of mathematical models used to model the diabetic Computational patient, i.e. RAS
5.1, diabetic 5.2, circulatory 5.3, and stiffness 5.4 models. Fig. 3 shows a schematic representation of the computational
system. The Computational patient can be customised in two different ways. First, the system has been designed in
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Figure 3: Schematic representation of the circulatory system composed of heart, pulmonary circulation, systemic
circulation, and baroreceptors (left). External factors affecting the renin-angiotensin system (ACEi and SARS-CoV-2)
are shown in violet (right).
Illustrations adapted from The Sourcebook of medical illustration [18].
order to be personalised using patient-specific values for some parameters such as age, glucose levels, arterial blood
pressure, presence of comorbidities or treatments (see Table 1). Should the physiological analysis require the inclusion
of additional conditions, new modules can be included and composed according to patient’s needs.
Table 1: Computational patients’ customisable parameters.
Class Parameter Description Values Units
Clinical record
A Age 20− 70 years
Glucose Blood glucose levels 100− 200 ml/dl
ABP Arterial blood pressure (from clinical records, e.g. [12]) 80− 120 mmHg
Comorbidities
infection Presence/absence of SARS-CoV-2 infection {True,False} -
renal Normal/impaired renal function {True,False} -
Treatments
drug Presence/absence of ACEi treatments {True,False} -
d ACEi dosage (Benazepril) 0− 5 mg
nd Number of daily drug administrations {0, 1} -
Lifestyle
tw Daily workout starting time 6 p.m. -
zw Daily workout intensity (burned calories) 200 kcal
tm Daily meals’ starting time {8 a.m. , 12 p.m. , 8 p.m.} -
gm Daily meals’ glycemic load {4, 42, 42} -
sm Daily meals’ carbohydrate serving {50, 100, 100} g
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5.1 Renin-angiotensin system and blood pressure regulation
The biochemical reaction network used to model the renin-angiotensin system is shown in Fig. 3. External factors
include hypertension treatments and viral infections binding to ACE2, such as SARS-CoV-2. Hypertension drugs
usually target ACE inhibiting ANG II production. ANG II promotes vasoconstriction, hypertension, inflammation,
and fibrosis by activating AT1R. Therefore, reducing ANG II production with ACE inhibitors increases vasodilation
and vasoprotection effects stimulated by AT2R and ANG-(1-7). On the other hand, SARS-CoV-2 infections reduce
ANG-(1-7) and ANG-(1-9) production rate, by binding to ACE2 in order to gain entry into the host cell. Hence,
vasoprotection effects promoted by ANG-(1-7) decline, possibly leading to hypertension and inflammatory response.
5.1.1 Pharmacokinetic model
Pharmacokinetic (PK) models are used to describe drugs absorption and excretion dynamics. Equation 1 describes
the analytical solution of a single-compartment pharmacokinetic model with first-order absorption and first-order
elimination rates after oral administration [46]. The equation has been used to model ACE inhibitors’ dynamics and
their effects on the RAS. A uniform dose size d at constant time intervals τ has been assumed [47]:
[Drug]n(t
′) = d
kaF
(ka − ke)V
(
1− exp(−nkeτ)
1− keτ exp−ket
′ − 1− exp(−nkaτ)
1− kaτ exp−kat
′
)
(1)
where [Drug]n(t′) is the drug concentration after the n-th dose, t′ = t(n− 1)τ is the time after the n-th dose, ka and
ke are the absorption and elimination rates respectively, F is the absorbed fraction of the drug, and V the volume of
distribution.
Pharmacokinetic parameters have been reported in table 3.
5.1.2 Pharmacodynamic model
Pharmacodynamic models are used to illustrate the effects of drug treatments on the body. The pharmacodynamic
model used to describe local RAS dynamics has been derived from [48, 14] (see Eqs. 15-19). The original model has
been extended with four additional equations (Eqs. 2-5). The variation of [ANG17], [AT1R] and [AT2R] have been
included as their dynamics can be useful in understanding how RAS regulates blood pressure [49]. The concentration
of ANG-(1-7) depends on the activity of two enzymes, NEP and ACE2, cleaving ANG-I and ANG-II respectively.
[AT1R] and [AT2R] rather depend on [ANGII] and on glucose concentration G.
d[ANG17]
dt
=
NEP-catalyzed conversion of ANG I︷ ︸︸ ︷
kNEP [ANGI] +
ACE2-catalyzed conversion of ANG II︷ ︸︸ ︷
kACE2[ANGII] −
degradation︷ ︸︸ ︷
ln 2
hANG17
[ANG17] (2)
d[AT1R]
dt
=
ANG-II bounds︷ ︸︸ ︷(
aAT1RG+ bAT1R
)
[ANGII]−
degradation︷ ︸︸ ︷
ln 2
hAT1R
[AT1R] (3)
d[AT2R]
dt
=
ANG-II bounds︷ ︸︸ ︷
kAT2R[ANGII]−
degradation︷ ︸︸ ︷
ln 2
hAT2R
[AT2R] (4)
The dynamics of ACE2 activity (kACE2) has been introduced as an indicator of SARS-CoV-2 infectivity [45]:
dkACE2
dt
=
{
sV [ANGII]− eAIkACE2 during SARS-CoV-2 infection
0 otherwise
(5)
where sV represents the severity of the viral infection and eAI the efficiency of anti-inflammatory pathways. A higher
concentration of [ANGII] may also induce cells to produce more ACE2, thus increasing its activity [45] and enhancing
viral entry. Hence ACE-inhibitor treatments may have a protective role as they reduce ACE activity lowering ANG-II
levels (see Fig. 3).
Pharmacodynamic parameters and initial conditions have been reported in table 4.
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5.2 Adding comorbidities: Type 2 Diabetes
Type 2 diabetes is a metabolic progressive disease over time whose progression and severity is caused by increasing
failure of insulin-production due to beta cell death.
There are complex multifactorial links between diabetes and cardiovascular disease [50, 51, 52, 53]. The main
pathophysiology cornerstone is a state of chronic, low-level inflammation. This immune activation may facilitate both
the insurgence and progression of insulin resistance in diabetic and pre-diabetic states and increases their cardiovascular
risk. An extension of a model from Topp and collaborators (Eqs. 6-9) combines insuline resistance, functional β-cell
mass dynamics with glucose dynamics and insulin dynamics [13]. The insulin and glucose dynamics are faster than the
beta cell dynamics. Mild hyperglycaemia leads to increasing beta cell numbers, but above a threshold of 250mg/dL
blood glucose, beta cell death is greater than cell division. Additional terms (not shown) include and non-functional beta
cells (βf and βnf ), activated macrophage, pathogenic T cells, insulin resistance, mTOR levels and beta cell antigenic
protein concentrations [54]. The distinction between beta cells into functioning and non-functioning cells allows to
take into account for the reduction and exhaustion of insulin produced by the beta cells. Although the preliminary
outcomes of the DIRECT study suggests that beta cells can be restored to normal function through the removal of
excess fat in the cells [55, 56], we have not taken into account the recovery of the pancreatic function. Inflammation
is key in diabetes, and the interaction between inflammation and metabolism can be considered a key homeostatic
mechanism [57]. The model considers both the effect of exercise and dietary [58]. This model was analysed using
sensitivity analysis and investigation to determine its properties (not shown). Sensitivity analyses are commonly used in
inverse modelling to determine how significant each parameter is to the output variables of the system. A local analysis
describes the sensitivity relative to point estimates of the parameters whereas a global analysis examines the entire
parameter distribution.
dG
dt
= R0 −G
(
EG0 +
effect of insulin resistance︷ ︸︸ ︷
SI
I
IR + i
)
+
diet︷ ︸︸ ︷
R1Hm(t)−
workouts︷ ︸︸ ︷
R2Hw(t) (6)
dI
dt
= σ
effect of glucose︷ ︸︸ ︷
βfG
2
α+G2
−kI (7)
dβf
dt
= −r0 + r1G− r2G2β (8)
dIR
dt
= −i0IR +
pro-inflammatory cytokines︷ ︸︸ ︷
mCyt +qI (9)
where G is the glucose concentration, I is Insulin concentration, βf functioning β-cells, IR insulin resistance, and Cyt
is the concentration of pro-inflammatory cytokines [59, 60, 61]. Hm and Hw are two step functions describing glucose
intake during meals and glucose consumption during workouts respectively:
Hm =
∑
i
gm,ism,iItm,i(1+∆m)(t) (10)
Hw =
∑
i
zw,iItw,i(1+∆w)(t) (11)
where gm is the glycemic load, sm the carbohydrate serving, and tm the meal starting time; zw the number of burned
calories and tw the workout starting time; Itm,i(1+∆m)(t) and Itw,i(1+∆w)(t) are indicator functions.
Here we consider progressive alteration of arterial stiffness and hypertension in diabetic patients. It is noteworthy
that low chronic inflammation related to metabolic active abdominal obesity (abnormal secretion of adipokines and
cytokines like TNF-alfa and interferon) and the impaired immune-response to infection (abnormal cytokine profile and
T-cell and macrophage activation) cause an increased risk for COVID-19 severity. Diabetic patients are frailer with
respect to normal population against COVID-19 multi-organ and multi-process disruption.
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5.3 Circulatory system model
Circulatory system models are used to describe blood flow, volume, and pressure dynamics. Equations 20-116 illustrate
a simplified open-loop cardiovascular model composed of five components: heart (20-40), systemic circulation (41-75),
pulmonary circulation (76-89), coronary circulation (90-105), and baroreceptors (106-110). Equations have been derived
from the open-loop circulatory model proposed in [12]. The heart model is composed of four sections (chambers)
corresponding to right atrium, right ventricle, left atrium, and left ventricle. Each chamber is modeled as a bellows
pump comprised of a one-way valve (pulmonary, tricuspid, mitral, and aortic) and a time-varying elastance (Eq. 27)
controlling blood outflow [62, 63]. Blood inflow is passive. The systemic circulation has been modeled with seven
vascular segments: proximal aorta, distal aorta, arteries, arterioles, capillaries, veins, and the vena cava. Each vessel
has been designed using a resistance element reflecting the impact on blood flow reduction and a compliance element
indicating the tendency of arteries and veins to stretch in response to pressure. High-frequency effects caused by wave
reflections at great arterial bifurcations (distal and proximal aorta) are modeled with inertance elements. Arterioles,
veins and vena cava have unique nonlinear PV relationships as described in [64] (see Eqs. 49-51, 53, and 41). The
pulmonary circulation is composed of five vascular segments: proximal and distal pulmonary artery, small arteries,
capillaries, and veins. Wave reflections in the proximal and distal pulmonary arteries are modeled with inertance
elements. The coronary circulation model consists of four segments: epicardial and intramiocardial arteries, coronary
capillaries, and coronary veins. Following [12], large and small artery and vein segments proposed in [65] have been
condensed into intramiocardial arteries and coronary veins, respectively. Baroreceptors are special sensory neurons that
are excited by a stretch in the carotid sinus and aortic arch vessels. Their feedback is processed by the brain in order
to maintain proper blood pressure. Baroreceptors’ firing frequency to the brain has been modeled as a second-order
response to the aortic pressure change [66, 64]. The second-order differential equation has been rewritten into two first
order equations in order to make it compatible with common Python solvers (Eqs. 108 and 109).
Circulatory system parameters and initial conditions have been reported in table 7.
5.4 Stiffness model
The complexity underlying multifactorial diseases requires the introduction of computational systems representing
multi-organ and inter-process communication. To this aim, we propose a mathematical model describing the impact of
comorbidities on the circulatory system. Several factors influencing blood pressure and arterial stiffness have been
modeled including: diabetes, renal impairments, viral infections, lifestyle and ageing.
Ageing affects the circulatory system in multiple ways. Baroreceptors’ feedback and pathways to the heart’s pacemaker
system decrease their efficiency over time. Heart muscle cells tend to degenerate and its walls get thicker slowing down
the time the heart takes to fill with blood increasing pressure on the vessels. Besides, blood vessels show a decreased
performance, since arteries tend to narrow and become more rigid.
Glucose concentration affects the renin-angiotensin-aldosterone pathway as it controls the concentration and activity
of Renin, ACE, and AT1R. AT1R activity is strongly related to vasoconstriction, hypertension, and inflammatory
response. Hence, arterial stiffness gets even worse increasing the risks of clogged arteries and strokes. Besides,
SARS-CoV-2 strongly bind to ACE2 decreasing its availability and impacting downstream RAS pathways regulating
blood pressure. Lower levels of available ACE2 reduce the concentration of ANG-(1-7), the endogenous ligand for the
G protein-coupled receptor MAS, a receptor associated with cardiac, renal, and cerebral protective responses. Hence,
vasoprotection and hypotension feedbacks deteriorate increasing inflammatory response and pressure on blood vessels.
The combined effect of comorbidities and ageing factors on arterial stiffness and inflammation may lead to critical
circulatory conditions and fibrosis. High glucose concentrations strengthen RAS hypertension feedbacks and lower
blood vessels’ lumen, especially on capillaries, arterioles, and venules. By affecting blood pressure regulation pathways,
SARS-CoV-2 infections may impair vasoprotection regulation by the RAS endangering the whole circulatory system
with disruptive repercussions among the elderly. The combination of all such factors may lead to acute diseases such
as thrombophlebitis, cardiomyopathy, myocardial infarction, pulmonary embolism, heart failure, and eventually to
patients’ death.
The diabetic model (Sec. 5.2) accounts both for hyperglycemic conditions and lifestyle habits. After lunch and
dinner, glucose concentration in blood vessels peaks, while it is scaled down by insulin or physical exercise. The RAS
model (Sec. 5.1) has been used to simulate peptides’ and drug concentration dynamics taking into account glucose
concentration, ACE inhibitor treatments, renal conditions, and viral infections binding to ACE2 (such as COVID19).
Abnormal ACE2 activity (kACE2 − kACE2,0) has been assumed as proportional to SARS-CoV-2 infectivity (see Eq. 5).
ACEi or ARB treatments could also increase ACE2 abundance and thus enhance viral entry [45]. In case of severe renal
conditions, only a fraction of drug diacid is expelled before the subsequent administration (see Eq. 1 and Fig. 4). The
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drug surplus left inside the body may reinforce inflammation. Overall, the inflammatory response has been modeled as
a function of all such contributions:
dIR
dt
=
viral infection︷ ︸︸ ︷
kSARS(kACE2 − kACE2,0)+
drug treatment︷ ︸︸ ︷
kD[Drug] +
glucose︷︸︸︷
kGG −
anti-inflammatory response︷ ︸︸ ︷
keff IR (12)
where kSARS represents SARS-CoV-2 affinity with ACE2, kD the inflammation rate due to ACEi surplus, kG the
inflammation rate due to glucose surplus, and keff the anti-inflammatory response rate.
One of the main processes associated with arterial stiffness occurring during ageing is DNA methylation, consisting in
the addition of methyl groups to the DNA molecule which may modify the activity of a DNA segment without changing
the sequence. DNA methylation has been modeled as a linear function of the age A [27]:
αMET = β0 − β1A β0,1 ≥ 0 (13)
As a result, blood vessels’ compliance parameters have been reduced by a factor accounting for the combined effect of
inflammation (Eq. 12) and ageing (Eq. 13):
Ĉi =
stiffness︷ ︸︸ ︷
αMET
(
1− IR
100
)
Ci (14)
where Ci is the compliance of the blood vessel i for a young healthy individual and Ĉi is the reduced compliance. The
circulatory model (Sec. 5.3) has been used to simulate blood pressure dynamics in critical vessels where blood pressure
spikes may lead to acute diseases.
6 Experiments
The models presented in Section 5 have been solved to analyze the effects of comorbidities like diabetes, renal
impairment, and viral infections affecting the circulatory system. Table 2 reports the set of experimental conditions that
have been analysed. Five Computational patients have been created corresponding to different physiological states.
These scenarios have been further stratified by the age of the Computational patient, given that arterial stiffness has been
modeled as a function of the increased DNA methylation during ageing. Drug concentrations (Fig. 4), inflammation
levels, and blood pressure dynamics in lungs’ vessels (Fig. 5) in comorbid conditions have been compared to the
dynamics obtained in healthy states or using ACE inhibitor treatments.
Table 2: Computational patients’ conditions used for the simulations. The diabetic and the RAS models do not depend
on patient’s age. Lifestyle habits have been set as three meals and one light workout session in the afternoon for all
patients.
Label Age Description
H 20 Healthy individual
D - Diabetic individual
R - Individual with renal impairment
C+T 70 Individual with comorbid conditions (diabetes + renal impairment) treated with ACEi
V 70 Individual with COVID19
C+V 70 Individual with comorbid conditions and COVID19
C+V+T 70 Individual with comorbid conditions and COVID19 treated with ACEi
The RAS model has been simulated for constant glucose cases using the daily glucose peak predicted by the diabetic
model right after the main meals. Glucose concentration ranged between the extremes of normal glucose at 6 − 7
mmol/L (corresponding to 108 − 125 ml/dl) and high glucose at 10 − 11 mmol/L (corresponding to 180 − 200
ml/dl) based on experimental studies [67, 68, 69]. The time window of the RAS simulations has been set to five
10
A PREPRINT - JUNE 12, 2020
0 1 2 3 4 5
time [days]
0
20
40
60
80
dr
ug
 d
ia
cid
 [n
g/
m
l]
H
R
10 15 20 25
insulin [mU/ml]
80
100
120
140
160
180
200
gl
uc
os
e 
[m
l/d
l]
H
D
Figure 4: Drug concentration for healthy individuals and patients with renal impairments (left). Glucose-insulin phase
space for healthy and diabetic individuals (right).
days, corresponding to five daily ACEi administrations [44]. The simulation results have been used to compute
arterial stiffness and to reduce compliance parameters of blood vessels in the open-loop circulatory model. In the
following simulations the arterial blood pressure (ABP) signal used in [12] has been used instead of personalised
clinical measurements.
Fig. 4 shows the dynamics of the concentration of ACEi and glucose-insulin dynamics over the first five days of
treatment. Due to renal impairment, the Computational patient was not able to expel the drug dose before the next
administration. The inflammatory response and the corresponding blood pressure dynamics in lungs’ vessels are shown
in Fig. 5. Comorbid conditions tend to increase blood pressure variability in all scenarios. However, as arterial stiffness
grows with the age of the Computational patient, the variability increases as well, possibly leading to irreversible
deterioration of blood vessels’ walls. ACEi treatments may help in reducing inflammation levels, but may not be
sufficient to recover healthy blood pressures. One of the most serious effects illustrated by simulations consists of
an increased mean value of blood pressure and blood pressure variability especially on small pulmonary vessels and
capillaries (see Fig. 5), increasing the risk of clogged arteries, fibrosis, and strokes. Besides, experimental results
shows how variables fluctuations over time may change and present different shapes especially on small vessels. In
Computational patients with comorbidities blood pressure dynamics in pulmonary capillaries exhibit higher mean
values and variability, but beat frequencies can be observed as well.
6.1 COVID19
The mortality statistics remarks the relevance of deeper analysis on multi-factorial diseases in fighting the COVID-19
pandemia [9]. Underlying morbidities such as cardiovascular disease, kidney disease, T2D or tumours have been
observed in patients with severe infection, especially among the elderly [10]. By affecting blood pressure regulation
pathways, SARS-CoV-2 infections may impair vasoprotection regulation endangering the whole circulatory system
with severe repercussions. By taking advantage of our composable framework, experimental results offer an overview
on how the combination of multiple diseases with SARS-CoV-2 may lead to acute conditions. Fig. 5 clearly shows how
the Computational patient with comorbidities and SARS-CoV-2 has higher risk of pulmonary vessels’ deterioration.
It is noteworthy that autopsy-based findings have evidenciated a variety of damages caused by COVID-19 infection,
among which extensive coagulopathy, acquired thrombophilia and endothelial cell death [70]. Here we consider the
sole effect on blood pressure.
7 Discussion
The modularity and composability of different available mechanistic and phenomenological models presents the chal-
lenge to define a mathematical framework connecting different systems’ descriptions, their dynamics, and constraints.
Let’s imagine to put together a model based on ODEs and a model in terms of a discrete space discrete time Markov
chain. This has then to be done in the light of behavioral properties that can be sets of trajectories or measures on
the trajectory space (typically those learned from data with statistical methods). Cell-level models (using ODEs,
delay differential equations, DDE, or agents) need to be systematically scaled up to the tissue level; for the multiple
timescale problems, the challenge is to obtain a model order reduction, i.e. to abandon high dimensional bioengineering
systems in favour of simpler effective mathematical models. The tissue level could be modeled using PDE or cellular
Potts model which may provide better representation for detailed and heterogeneous cell-cell, cell-tissue, cell-matrix
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Figure 5: Inflammation scores (top-left, see Eq. 12), the corresponding lungs’ pressures phase space (top-right) and
dynamics over time (bottom)
interaction cases. Integrative models, could be made by single scale models, describing the biological process at
different characteristic space-time scales, and scale bridging models, which define how the component models are
coupled to each other. While at the tissue level, physical quantities usually vary across space and time, in a continuous
fashion, and can be thus represented using systems of PDE [71].
7.1 Emerging properties of variances from model composability
Many physiological variables have a circadian trend; sometimes also a seasonal one. For example blood pressure
decreases during sleep and shows a sharp uprise at the time of awakening. This early morning variation is often
concurrent with an increase of acute myocardial infarction, sudden cardiac death, and stroke. [72]. Common clinical
parameters such as diastolic and systolic blood pressure, heart patterns, blood cell counts are usually evaluated as
averages. Little importance is given to higher moments such as variances during the day or during a longer interval of
time. The lack of continuous measures for most of the quantities has generated a medical practice that disregard of
unobserved or partially observed data. Some authors identified a disease and age-related loss of complex variability in
multiple physiologic processes including cardiovascular control, pulsatile hormone release, and ecg data [73, 74]. Our
composable model reveals interesting patterns, particularly fluctuations in blood pressure, particularly during COVID
acute infection when the diabetic model is coupled with the RAS and the cardiovascular models. We believe that the
use of extensive models could enable to understand concurrent patterns of alteration in different districts.
7.2 How such Computational patient model could be deployed and further developed
Computational Patient will benefit from using machine learning and data analysis of large amount of data such for
instance that obtained from UK Biobank as modeling will have a truly catalytic effect in synergy with machine learning.
The Computational patient model requires adequate artificial intelligence support to generate diagnosis and validate its
correctness. A decision-making process could be based on the development of a personalised statistics of Changes
in Health, End-stage disease, and Signs and Symptoms [75]. This ideally would develop through monitoring of the
individualized response to therapeutic interventions, in addition to changes in risk profile. One aspect is a dedicated
CHESS-(“Changes in Health, End-stage disease, and Signs and Symptoms” (CHESS) scale based on all the variables
and observable considered considered by the model(s) [75, 76]. It will act as a Personalised Patient simulator and will
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draw temporal trajectories of disease and comorbidities progression. The trajectories will change with drug regimen,
medical intervention, and lifestyle changes.
Any data used will be anonymises or de-identified using ad hoc software (see for instance [77]) and we will follow the
FAIR principle (Findable, Accessible, Interoperable, Reusable) and the GRPD regulation. One meaningful approach to
extract useful indication is to use a clinical decision support system such as the one described in [78] which incorporates
medical experience, research results and personal judgement. We believe the Computational patient models to be in a
research only state and therefore we do not make further integrations.
The future foreseen is that AI will assist our health and disease conditions in a more effective way than nowadays: a
medical check up will be supported by well-tuned artificial intelligence and patient-based modeling . At the clinical
level, computer-aided therapies and treatments will develop into intervention strategies undertaken under acute disease
conditions or due to external factors (infections) to contrast cascade effects. In non acute states, predictive inference
will propose prevention plans for comorbidity management, particularly in presence of multiple therapies.
Therefore this approach is meaningful in perspective of a computational medicine characterised by a close coupling
between bioinformatics, clinical measures and modeling prediction and perhaps remote patient monitoring.
8 Conclusion
Computational scientists and bioengineers’ vision is a framework of methods and technologies that, once established,
will make it possible to investigate the human body as a whole. It calls for a total transformation in the way healthcare
currently works and is delivered to patients. Underpinning this transformation is substantial technological innovation
with a requirement for deeper trans-disciplinary research, improved IT infrastructure, better communication, large
volumes of high quality data and machine learning and modeling tools. Machine learning could be automatised (i.e.
autoML) and models should be modular so to be organised to answer specific and personalised medical questions.
Simulations are increasingly regarded as valuable tools in a number of aspects of medical practice including lifestyle
changes, surgical planning and medical interventions. The idea is that cross-modality data is obtained for the patient
and machine learning techniques estimate parameters to be input into modeling framework. We believe that a deeper
understanding and practice of modeling in medicine will produce better investigation of complex biological processes,
and even new ideas and better feedback into medicine. Finally, computational models are cheap and this will make
possible to predict drugs interaction and to make better use of generic drugs. In this sense the personalised model will
become a product associated with the drug.
8.1 Disclaimer
The computational tool has not been validated and should not be used for clinical purposes.
To enable code reuse, the Python code for the mathematical models including parameter values and documentation is
freely available under Apache 2.0 Public License from a GitHub repository [19]. Unless required by applicable law or
agreed to in writing, software is distributed on an "as is" basis, without warranties or conditions of any kind, either
express or implied.
9 Acknowledgement
The authors have received funding from the European Union’s Horizon 2020 research and innovation programme under
grant agreement No 848077. We thank Gianluca Ascolani, Rachel Clark, Annalisa Occhipinti, Stefan Stojanovic for
suggestions.
References
[1] Gianluca Ascolani, Annalisa Occhipinti, and Pietro Liò. Modelling circulating tumour cells for personalised
survival prediction in metastatic breast cancer. PLOS Computational Biology, 11(5):e1004199, May 2015.
[2] E. Giampieri, D. Remondini, L. de Oliveira, G. Castellani, and P. Lió. Stochastic analysis of a miRNA–protein
toggle switch. Molecular BioSystems, 7(10):2796, 2011.
[3] Joëlle Despeyroux, Amy Felty, Pietro Liò, and Carlos Olarte. A logical framework for modelling breast cancer
progression. In Molecular Logic and Computational Synthetic Biology, pages 121–141. Springer International
Publishing, 2019.
13
A PREPRINT - JUNE 12, 2020
[4] Ezio Bartocci and Pietro Lió. Computational modeling, formal analysis, and tools for systems biology. PLoS
computational biology, 12(1), 2016.
[5] Ezio Bartocci, Pietro Liò, Emanuela Merelli, and Nicola Paoletti. Multiple verification in complex biological
systems: the bone remodelling case study. In Transactions on Computational Systems Biology XIV, pages 53–76.
Springer, 2012.
[6] Sandip Ray, Markus Britschgi, Charles Herbert, Yoshiko Takeda-Uchimura, Adam Boxer, Kaj Blennow, Leah F
Friedman, Douglas R Galasko, Marek Jutel, Anna Karydas, et al. Classification and prediction of clinical
alzheimer’s diagnosis based on plasma signaling proteins. Nature medicine, 13(11):1359–1362, 2007.
[7] Nobuyuki Sudo, Yoichi Chida, Yuji Aiba, Junko Sonoda, Naomi Oyama, Xiao-Nian Yu, Chiharu Kubo, and
Yasuhiro Koga. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress
response in mice. The Journal of Physiology, 558(1):263–275, June 2004.
[8] Sirisha Achanta, Jonathan Gorky, Clara Leung, Alison Moss, Shaina Robbins, Leonard Eisenman, Jin Chen, Susan
Tappan, Maci Heal, Navid Farahani, Todd Huffman, Steve England, Zixi (Jack) Cheng, Rajanikanth Vadigepalli,
and James S. Schwaber. A comprehensive integrated anatomical and molecular atlas of rat intrinsic cardiac
nervous system. iScience, page 101140, May 2020.
[9] Bertrand Cariou, , Samy Hadjadj, Matthieu Wargny, Matthieu Pichelin, Abdallah Al-Salameh, Ingrid Allix,
Coralie Amadou, Gwénaëlle Arnault, Florence Baudoux, Bernard Bauduceau, Sophie Borot, Muriel Bourgeon-
Ghittori, Olivier Bourron, David Boutoille, France Cazenave-Roblot, Claude Chaumeil, Emmanuel Cosson,
Sandrine Coudol, Patrice Darmon, Emmanuel Disse, Amélie Ducet-Boiffard, Bénédicte Gaborit, Michael Joubert,
Véronique Kerlan, Bruno Laviolle, Lucien Marchand, Laurent Meyer, Louis Potier, Gaëtan Prevost, Jean-Pierre
Riveline, René Robert, Pierre-Jean Saulnier, Ariane Sultan, Jean-François Thébaut, Charles Thivolet, Blandine
Tramunt, Camille Vatier, Ronan Roussel, Jean-François Gautier, and Pierre Gourdy. Phenotypic characteristics
and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia, May 2020.
[10] Tianbing Wang, Zhe Du, Fengxue Zhu, Zhaolong Cao, Youzhong An, Yan Gao, and Baoguo Jiang. Comorbidities
and multi-organ injuries in the treatment of COVID-19. The Lancet, 395(10228):e52, March 2020.
[11] Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, James M. Crawford, Thomas McGinn, Karina W.
Davidson, Douglas P. Barnaby, Lance B. Becker, John D. Chelico, Stuart L. Cohen, Jennifer Cookingham, Kevin
Coppa, Michael A. Diefenbach, Andrew J. Dominello, Joan Duer-Hefele, Louise Falzon, Jordan Gitlin, Negin
Hajizadeh, Tiffany G. Harvin, David A. Hirschwerk, Eun Ji Kim, Zachary M. Kozel, Lyndonna M. Marrast,
Jazmin N. Mogavero, Gabrielle A. Osorio, Michael Qiu, and Theodoros P. Zanos and. Presenting characteristics,
comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new york city area. JAMA,
April 2020.
[12] Maxwell Lewis Neal and James B Bassingthwaighte. Subject-specific model estimation of cardiac output and
blood volume during hemorrhage. Cardiovascular engineering, 7(3):97–120, 2007.
[13] B Topp, K Promislow, G Devries, RM Miuraa, and DT Finegood. A Model of β−cell mass, insulin and glucose
kinetics: Pathways to diabetes. J. theor. Biol., 206:605–609, 2000. doi:10.1006/jtbi.2000.2150.
[14] Minu R Pilvankar, Hui Ling Yong, and Ashlee N Ford Versypt. A glucose-dependent pharmacoki-
netic/pharmacodynamic model of ace inhibition in kidney cells. Processes, 7(3):131, 2019.
[15] Peter Hunter, Peter Robbins, and Denis Noble. The iups human physiome project. Pflügers Archiv, 445(1):1–9,
2002.
[16] S Van Sint Jan, M Viceconti, and G Clapworthy. The europhysiome: towards an infrastructure for a more
integrated research. Journal of biomechanics, 40:S282, 2007.
[17] Jeremy Gunawardena. Models in systems biology: the parameter problem and the meanings of robustness.
Elements of Computational Systems Biology. New Jersey: John Wiley and Sons, pages 21–48, 2010.
[18] Peter Cull. The Sourcebook of medical illustration: over 900 anatomical, medical, and scientific illustrations
available for general re-use and adaptation free of normal copyright restrictions. Parthenon Publishing, 1989.
[19] Pietro Barbiero and Pietro Liò. https://github.com/pietrobarbiero/computational-patient.
[20] Alan C Hindmarsh. Odepack, a systematized collection of ode solvers. Scientific computing, pages 55–64, 1983.
[21] Linda Petzold. Automatic selection of methods for solving stiff and nonstiff systems of ordinary differential
equations. SIAM journal on scientific and statistical computing, 4(1):136–148, 1983.
[22] Fernando Pérez, HP Langtangen, and R LeVeque. Python for scientific computing. In SIAM Conference on
Computational Science and Engineering, volume 42, 2009.
14
A PREPRINT - JUNE 12, 2020
[23] Katherine Howell, Henry Ooi, Rob Preston, and Paul McLoughlin. Structural basis of hypoxic pulmonary
hypertension: the modifying effect of chronic hypercapnia. Experimental Physiology, 89(1):66–72, December
2003.
[24] Bum Joon Kim, Sun U. Kwon, Dalia Wajsbrot, Jaseong Koo, Jong Moo Park, and Barrett W. Jeffers. Relationship
of inter-individual blood pressure variability and the risk for recurrent stroke. Journal of the American Heart
Association, 7(24), December 2018.
[25] Y Tao, J Xu, B Song, X Xie, H Gu, Q Liu, L Zhao, Y Wang, Y Xu, and Y Wang. Short-term blood pressure
variability and long-term blood pressure variability: which one is a reliable predictor for recurrent stroke. Journal
of Human Hypertension, 31(9):568–573, April 2017.
[26] Igor A. Fernandes, Marcos P. Rocha, Monique O. Campos, João D. Mattos, Daniel E. Mansur, Helena N. M. Rocha,
Paulo A. C. Terra, Vinícius P. Garcia, Natália G. Rocha, Niels H. Secher, and Antonio C. L. Nóbrega. Reduced
arterial vasodilatation in response to hypoxia impairs cerebral and peripheral oxygen delivery in hypertensive men.
The Journal of Physiology, 596(7):1167–1179, February 2018.
[27] Wen Wen, Rong Luo, Xiaojing Tang, Lan Tang, Hunter X. Huang, Xiaoyan Wen, Shan Hu, and Bin Peng.
Age-related progression of arterial stiffness and its elevated positive association with blood pressure in healthy
people. Atherosclerosis, 238(1):147–152, January 2015.
[28] Michael F. O’Rourke and Wilmer W. Nichols. Aortic diameter, aortic stiffness, and wave reflection increase with
age and isolated systolic hypertension. Hypertension, 45(4):652–658, April 2005.
[29] Gary F. Mitchell, Shih-Jen Hwang, Ramachandran S. Vasan, Martin G. Larson, Michael J. Pencina, Naomi M.
Hamburg, Joseph A. Vita, Daniel Levy, and Emelia J. Benjamin. Arterial stiffness and cardiovascular events.
Circulation, 121(4):505–511, February 2010.
[30] Sripal Bangalore, David J. Maron, Sean M. O’Brien, Jerome L. Fleg, Evgeny I. Kretov, Carlo Briguori, Upendra
Kaul, Harmony R. Reynolds, Tomasz Mazurek, Mandeep S. Sidhu, Jeffrey S. Berger, Roy O. Mathew, Olga
Bockeria, Samuel Broderick, Radoslaw Pracon, Charles A. Herzog, Zhen Huang, Gregg W. Stone, William E.
Boden, Jonathan D. Newman, Ziad A. Ali, Daniel B. Mark, John A. Spertus, Karen P. Alexander, Bernard R.
Chaitman, Glenn M. Chertow, and Judith S. Hochman. Management of coronary disease in patients with advanced
kidney disease. New England Journal of Medicine, 382(17):1608–1618, April 2020.
[31] Donald Clark, Stephen J. Nicholls, Julie St John, Mohamed B. Elshazly, Haitham M. Ahmed, Haitham Khraishah,
Steven E. Nissen, and Rishi Puri. Visit-to-visit blood pressure variability, coronary atheroma progression, and
clinical outcomes. JAMA Cardiology, 4(5):437, May 2019.
[32] Tokuhisa Uejima, , Frank D. Dunstan, Eloisa Arbustini, Krystyna Łoboz-Grudzien´, Alun D. Hughes, Scipione Car-
erj, Valentina Favalli, Francesco Antonini-Canterin, Olga Vriz, Dragos Vinereanu, Jose L. Zamorano, Bogdan A.
Popescu, Arturo Evangelista, Patrizio Lancellotti, Georges Lefthériotis, Michaela Kozakova, Carlo Palombo, and
Alan G. Fraser. Age-specific reference values for carotid arterial stiffness estimated by ultrasonic wall tracking.
Journal of Human Hypertension, 34(3):214–222, August 2019.
[33] Iram Faqir Muhammad, Yan Borné, Gerd Östling, Cecilia Kennbäck, Mikael Gottsäter, Margaretha Persson,
Peter M. Nilsson, and Gunnar Engström. Arterial stiffness and incidence of diabetes: A population-based cohort
study. Diabetes Care, 40(12):1739–1745, September 2017.
[34] Min Xu, Ya Huang, Lan Xie, Kui Peng, Lin Ding, Lin Lin, Po Wang, Mingli Hao, Yuhong Chen, Yimin Sun, Lu Qi,
Weiqing Wang, Guang Ning, and Yufang Bi. Diabetes and risk of arterial stiffness: A mendelian randomization
analysis. Diabetes, 65(6):1731–1740, March 2016.
[35] Wei Gan, Fiona Bragg, Robin G. Walters, Iona Y. Millwood, Kuang Lin, Yiping Chen, Yu Guo, Julien Vaucher,
Zheng Bian, Derrick Bennett, Jun Lv, Canqing Yu, Anubha Mahajan, Robert J. Clarke, Liming Li, Michael V.
Holmes, Mark I. McCarthy, and Zhengming Chen. Genetic predisposition to type 2 diabetes and risk of subclinical
atherosclerosis and cardiovascular diseases among 160, 000 chinese adults. Diabetes, 68(11):2155–2164, August
2019.
[36] James M. Eales, Simon P.R. Romaine, Fadi J. Charchar, and Maciej Tomaszewski. A multi-omics glimpse into
the biology of arterial stiffness. Journal of Hypertension, 34(1):32–35, January 2016.
[37] Claudio Franceschi, Massimiliano Bonafè, Silvana Valensin, Fabiola Olivieri, Maria De Luca, Enzo Ottaviani,
and Giovanna De Benedictis. Inflamm-aging: an evolutionary perspective on immunosenescence. Annals of the
new York Academy of Sciences, 908(1):244–254, 2000.
[38] Irene Maeve Rea, David S. Gibson, Victoria McGilligan, Susan E. McNerlan, H. Denis Alexander, and Owen A.
Ross. Age and age-related diseases: Role of inflammation triggers and cytokines. Frontiers in Immunology, 9,
April 2018.
15
A PREPRINT - JUNE 12, 2020
[39] Sungha Park and Edward G. Lakatta. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Medical
Journal, 53(2):258, 2012.
[40] K. M. Madden, C. Lockhart, D. Cuff, T. F. Potter, and G. S. Meneilly. Short-term aerobic exercise reduces
arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Diabetes Care,
32(8):1531–1535, June 2009.
[41] John H Fountain and Sarah L Lappin. Physiology, renin angiotensin system. In StatPearls [Internet]. StatPearls
Publishing, 2019.
[42] Keiji Kuba, Yumiko Imai, Takayo Ohto-Nakanishi, and Josef M Penninger. Trilogy of ace2: A peptidase in the
renin–angiotensin system, a sars receptor, and a partner for amino acid transporters. Pharmacology & therapeutics,
128(1):119–128, 2010.
[43] Mariela M Gironacci, Hugo P Adamo, Gerardo Corradi, Robson A Santos, Pablo Ortiz, and Oscar A Carretero.
Angiotensin (1-7) induces mas receptor internalization. Hypertension, 58(2):176–181, 2011.
[44] Mohammad Amin Zaman, Suzanne Oparil, and David A Calhoun. Drugs targeting the renin–angiotensin–
aldosterone system. Nature reviews Drug discovery, 1(8):621–636, 2002.
[45] Andrew M South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath, and Matthew A Sparks. Controversies
of renin–angiotensin system inhibition during the covid-19 pandemic. Nature Reviews Nephrology, pages 1–3,
2020.
[46] Ashlee N Ford Versypt, Grace K Harrell, and Alexandra N McPeak. A pharmacokinetic/pharmacodynamic model
of ace inhibition of the renin-angiotensin system for normal and impaired renal function. Computers & Chemical
Engineering, 104:311–322, 2017.
[47] James P Byers and Jeffrey G Sarver. Pharmacokinetic modeling. In Pharmacology, pages 201–277. Elsevier,
2009.
[48] Minu R Pilvankar, Michele A Higgins, and Ashlee N Ford Versypt. Mathematical model for glucose dependence
of the local renin–angiotensin system in podocytes. Bulletin of mathematical biology, 80(4):880–905, 2018.
[49] Arthur Lo, Jennifer Beh, Hector De Leon, Melissa K Hallow, Ramprasad Ramakrishna, Manoj Rodrigo, Anamika
Sarkar, Ramesh Sarangapani, and Anna Georgieva. Using a systems biology approach to explore hypotheses
underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies. In
Clinical Trial Simulations, pages 457–482. Springer, 2011.
[50] S. Sharif, F. L. J. Visseren, W. Spiering, P. A. Jong, M. L. Bots, and J. Westerink and. Arterial stiffness as a
risk factor for cardiovascular events and all-cause mortality in people with type 2 diabetes. Diabetic Medicine,
36(9):1125–1132, April 2019.
[51] Rafael de Oliveira Alvim, Paulo Caleb Junior Lima Santos, Mariane Musso, Roberto de Sá Cunha, José Krieger,
José Mill, and Alexandre Pereira. Impact of diabetes mellitus on arterial stiffness in a representative sample of an
urban brazilian population. Diabetology & Metabolic Syndrome, 5(1):45, 2013.
[52] Yao Lu, Raimund Pechlaner, Jingjing Cai, Hong Yuan, Zhijun Huang, Guoping Yang, Jiangang Wang, Zhiheng
Chen, Stefan Kiechl, and Qingbo Xu. Trajectories of age-related arterial stiffness in chinese men and women.
Journal of the American College of Cardiology, 75(8):870–880, March 2020.
[53] Alejandro Diaz, Matías Tringler, Sandra Wray, Agustín J. Ramirez, and Edmundo I. Cabrera Fischer. The effects
of age on pulse wave velocity in untreated hypertension. The Journal of Clinical Hypertension, 20(2):258–265,
December 2017.
[54] K. Kodama, M. Horikoshi, K. Toda, S. Yamada, K. Hara, J. Irie, M. Sirota, A. A. Morgan, R. Chen, H. Ohtsu,
S. Maeda, T. Kadowaki, and A. J. Butte. Expression-based genome-wide association study links the receptor CD44
in adipose tissue with type 2 diabetes. Proceedings of the National Academy of Sciences, 109(18):7049–7054,
April 2012.
[55] Sviatlana V. Zhyzhneuskaya, Ahmad AL-Mrabeh, Alison C. Barnes, Benjamin Aribisala, Kieren G. Hollingsworth,
Helen Pilkington, Naveed Sattar, Michael E. Lean, and Roy Taylor. 66-OR: Remission of type 2 diabetes for two
years is associated with full recovery of beta-cell functional mass in the diabetes remission clinical trial (DiRECT).
Diabetes, 68(Supplement 1):66–OR, June 2019.
[56] Michael EJ Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie,
Carl Peters, Sviatlana Zhyzhneuskaya, Ahmad Al-Mrabeh, Kieren G Hollingsworth, Angela M Rodrigues,
Lucia Rehackova, Ashley J Adamson, Falko F Sniehotta, John C Mathers, Hazel M Ross, Yvonne McIlvenna,
Renae Stefanetti, Michael Trenell, Paul Welsh, Sharon Kean, Ian Ford, Alex McConnachie, Naveed Sattar, and
Roy Taylor. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label,
cluster-randomised trial. The Lancet, 391(10120):541–551, February 2018.
16
A PREPRINT - JUNE 12, 2020
[57] Gökhan S. Hotamisligil. Inflammation and metabolic disorders. Nature, 444(7121):860–867, December 2006.
[58] Matthias B Schulze, Kurt Hoffmann, JoAnn E Manson, Walter C Willett, James B Meigs, Cornelia Weikert,
Christin Heidemann, Graham A Colditz, and Frank B Hu. Dietary pattern, inflammation, and incidence of type 2
diabetes in women. The American Journal of Clinical Nutrition, 82(3):675–684, September 2005.
[59] DH Solomon, TJ Love, C Canning, and et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic
arthritis and psoriasis. Ann Rheum Dis., 69(12):2114–2117, 2010.
[60] CC Su, IeC Chen, FN Young, and et al. Risk of diabetes in patients with rheumatoid arthritis: a 12-year
retrospective cohort study. J Rheumatol., 40(9):1513–1518, 2013.
[61] MC Lu, ST Yan, WY Yin, and et al. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide
population-based case-control study. PLoS One, 9(7):e101528, 2014.
[62] Vincent C Rideout. Mathematical and computer modeling of physiological systems. Prentice Hall Englewood
Cliffs, NJ:, 1991.
[63] Thomas Heldt, Eun B Shim, Roger D Kamm, and Roger G Mark. Computational modeling of cardiovascular
response to orthostatic stress. Journal of applied physiology, 92(3):1239–1254, 2002.
[64] K Lu, JW Clark Jr, FH Ghorbel, DL Ware, and A Bidani. A human cardiopulmonary system model applied
to the analysis of the valsalva maneuver. American Journal of Physiology-Heart and Circulatory Physiology,
281(6):H2661–H2679, 2001.
[65] Daniel Zinemanas, Rafael Beyar, and Samuel Sideman. Relating mechanics, blood flow and mass transport in the
cardiac muscle. International journal of heat and mass transfer, 37:191–205, 1994.
[66] M Di Rienzo et al. Circulatory model of baro-and cardio-pulmonary reflexes. Blood Pressure and Heart Rate
Variability: Computer Analysis, Modelling and Clinical Applications, 4:56, 1993.
[67] Raghu V Durvasula and Stuart J Shankland. Activation of a local renin angiotensin system in podocytes by
glucose. American Journal of Physiology-Renal Physiology, 294(4):F830–F839, 2008.
[68] Benito Yard, Yuxi Feng, Hanno Keller, Christa Mall, and Fokko van der Woude. Influence of high glucose
concentrations on the expression of glycosaminoglycans and n-deacetylase/n-sulphotransferase mrna in cultured
skin fibroblasts from diabetic patients with or without nephropathy. Nephrology Dialysis Transplantation,
17(3):386–391, 2002.
[69] Falguni Das, Nandini Ghosh-Choudhury, Nirmalya Dey, Amit Bera, Meenalakshmi M Mariappan, Balakuntalam S
Kasinath, and Goutam Ghosh Choudhury. High glucose forces a positive feedback loop connecting akt kinase and
foxo1 transcription factor to activate mtorc1 kinase for mesangial cell hypertrophy and matrix protein expression.
Journal of Biological Chemistry, 289(47):32703–32716, 2014.
[70] Richard C. Becker. COVID-19 update: Covid-19-associated coagulopathy. Journal of Thrombosis and Thrombol-
ysis, May 2020.
[71] Marco Viceconti, Gordon Clapworthy, Debora Testi, Fulvia Taddei, and Nigel McFarlane. Multimodal fusion of
biomedical data at different temporal and dimensional scales. Computer Methods and Programs in Biomedicine,
102(3):227–237, June 2011.
[72] W ELLIOTT. Circadian variation in blood pressureImplications for the elderly patient. American Journal of
Hypertension, 12(2):43S–49S, February 1999.
[73] Lewis A. Lipsitz. Loss of ’complexity’ and aging. JAMA, 267(13):1806, April 1992.
[74] Leon Glass, Michael C. Mackey, and Paul F. Zweifel. From clocks to chaos: The rhythms of life. Physics Today,
42(7):72–72, July 1989.
[75] John P. Hirdes, Dinnus H. Frijters, and Gary F. Teare. The MDS-CHESS scale: A new measure to predict mortality
in institutionalized older people. Journal of the American Geriatrics Society, 51(1):96–100, January 2003.
[76] A E Ades, Nicky J Welton, Deborah Caldwell, Malcolm Price, Aicha Goubar, and Guobing Lu. Multiparameter
evidence synthesis in epidemiology and medical decision-making. Journal of Health Services Research & Policy,
13(3_suppl):12–22, October 2008.
[77] Rudolf N. Cardinal. Clinical records anonymisation and text extraction (CRATE): an open-source software system.
BMC Medical Informatics and Decision Making, 17(1), April 2017.
[78] Tamara T. Müller and Pietro Lio. PECLIDES neuro: A personalisable clinical decision support system for
neurological diseases. Frontiers in Artificial Intelligence, 3, April 2020.
17
A PREPRINT - JUNE 12, 2020
[79] Hiroshi Shionoiri, Shin-ichiro Ueda, Kohsuke Minamisawa, Mayumi Minamisawa, Izumi Takasaki, Koichi
Sugimoto, Eiji Gotoh, and Masao Ishii. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive
patients with normal and impaired renal function. Journal of cardiovascular pharmacology, 20(3):348–357, 1992.
[80] Shinji Hisatake, Shunsuke Kiuchi, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, and Takanori Ikeda. Serum
angiotensin-converting enzyme 2 concentration and angiotensin-(1–7) concentration in patients with acute heart
failure patients requiring emergency hospitalization. Heart and vessels, 32(3):303–308, 2017.
[81] Gianna Toffolo, Richard N Bergman, Diane T Finegood, Charles R Bowden, and Claudio Cobelli. Quantitative
estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog.
Diabetes, 29(12):979–990, 1980.
[82] Willy Malaisse, FRANCINE MALAISSE-LAGAE, and PETER H WRIGHT. A new method for the measurement
in vitro of pancreatic insulin secretion. Endocrinology, 80(1):99–108, 1967.
[83] Richard N Bergman, Lawrence S Phillips, and Claudio Cobelli. Physiologic evaluation of factors controlling
glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to
intravenous glucose. The Journal of clinical investigation, 68(6):1456–1467, 1981.
[84] Diane T Finegood. Application of the minimal model of glucose kinetics. The Minimal Model Approach and
Determinants of Glucose Tolerance, 7:51–122, 1997.
[85] Toshinori Imamura, Michael Koffler, J Harold Helderman, Dale Prince, Richard Thirlby, Lindsey Inman, and
Roger H Unger. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes,
37(5):600–609, 1988.
18
A PREPRINT - JUNE 12, 2020
A Appendix
A.1 Website
Figure 6: Website dashboard for Computational patients.
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A.2 Equations of the renin-angiotensin system
I =
100[DRUG]m
[DRUG]m50 + [DRUG]
m
(15)
d[AGT ]
dt
=
production rate︷ ︸︸ ︷
kAGT −
renin-catalyzed conversion to ANG I︷ ︸︸ ︷(
aReninG+ bRenin
)
[AGT ]−
degradation︷ ︸︸ ︷
ln(2)
hAGT
[AGT ] (16)
d[Renin]
dt
=
production rate︷ ︸︸ ︷
ln 2
hRenin
[Renin]0
+
ANG II inhibition feedback︷ ︸︸ ︷
kf,sys[ANGII]0,sys
[ANGII]0
(
[ANGII]0 − [ANGII]
)(
1− ([ANGII]0 − [ANGII]) [ANGII]0,sys
fsys[ANGII]0
)
−
degradation︷ ︸︸ ︷
ln 2
hRenin
[Renin] (17)
d[ANGI]
dt
=
renin-catalyzed conversion of AGT︷ ︸︸ ︷(
aReninG+ bRenin
)
[AGT ] +
ANG II feedback on renin︷ ︸︸ ︷
kRenin
(
[Renin]− [Renin]0
)
−
ACE-catalyzed conversion to ANG II subject to inhibition︷ ︸︸ ︷(
aACEG+ bACE
)
[ANGI]
(
1− I
)
−
conversion to ANG-(1-7) and ANG-(1-9)︷ ︸︸ ︷(
kNEP + kACE2
)
[ANGI] −
−
degradation︷ ︸︸ ︷
ln2
hANGI
[ANGI] (18)
d[ANGII]
dt
=
ACE-catalyzed conversion to ANG II subject to inhibition︷ ︸︸ ︷(
aACEG+ bACE
)
[ANGI]
(
1− I
)
−
conversion to AT1R, AT2R, APA, and ANG-(1-7)︷ ︸︸ ︷(
kACE2 +
(
aAT1G+ bAT1
)
+ kAT2 + kAPA
)
[ANGII]
−
degradation︷ ︸︸ ︷
ln2
hANGII
[ANGII] (19)
A.3 Equations of the open-loop circulatory model
A.3.1 Four-chambered heart
t ≥ tHB(n+ 1)− PRint − offv =⇒

HRa =
1
HP/60
Tsa = Ts1a
√
Ts2
HRa/60
tPwave = tHB − PRint − offv
n = n+ 1
(20)
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t ≥ tHB(m+1)−offv =⇒

HRv =
1
HP/60
Tsv = Ts1v
√
Ts2
HRv/60
tRwave = tHB − offv
m = n
Vvar,i,vs0 =

Vi,vd0 Vi,v < Vi,vd0
Vi,vs0 Vi,v > EDViv
Vi,vs0 − Vi,vd0 Vi,v − Vi,vd0
EDVi,v − Vi,vd0 + Vi,vd0 Vi,vd0 ≤ Vi,v ≤ EDViv
afcon2 = afcon
(21)
HR = HRv (22)
Emax,i,v = Ke,i,vEmax,i,v1 (23)
ta,REL = t− tPwave (24)
tv,REL = t− tRwave (25)
yi =

1− cospi ti,REL
Ts,i
2
0 ≤ ti,REL < Ts,i
1 + cos 2pi
ti,REL − Ts,i
Ts,i
2
Ts,i ≤ ti,REL < 1.5Ts,i
0 ti,REL ≥ 1.5Ts,i
(26)
Ei,j = yj(Emax,i,j − Emin,i,j) + Emin,i,j (27)
Vi,a,0 = (1− ya)(Vi,a,d0 − Vi,a,s0) + Vi,a,s0 (28)
Vi,v,0 = (1− yv)(Vi,v,d0 − Vvar,i,vs0) + Vvar,i,vs0 (29)
ψ(v) = Kxp
1
ev/Kxv − 1 (30)
Pi,a = Ei,a(Vi,a − Vi,a0)− ψ(Vi,a) (31)
Pi,v = Ei,v(Vi,v − Vi,v0)afcon2 − ψ(Vi,v) (32)
Fi,a =

Pi,a − Pi,v
Ri,a
Pi,a > Pi,v
0 Pi,a ≤ Pi,v
(33)
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Fr,v =

Pr,v − Ppap
Rr,v
Pr,v > Ppap
0 Pr,v ≤ Ppap
(34)
Fl,v =

Pl,v − Paop
Rl,v
Pl,v > Paop
0 Pl,v ≤ Paop
(35)
dVr,a
dt
= (36)
dVr,a
dt
=
Fvc + Fcorvn
Fr,a
(37)
dVr,v
dt
=
Fr,a
Frv
(38)
dVl,a
dt
=
Fpv
Fl,a
(39)
dVl,v
dt
=
Fl,a
Fl,v
(40)
A.3.2 Systemic circulation
Pvc =
{
K1(Vvc − Vvc0)− ψ(Vvc) Vvc > Vvc0
D2 +K2e
Vvc/Vmin,vc − ψ(Vvc) Vvc ≤ Vvc0
(41)
COmod = Frv,sm (42)
SV =
COmod
HR
(43)
ABPshift = ABPmeas(t− offv) (44)
Kv = Kv1Ksv (45)
MAPmod =
Rcrb
[
RtaodAOFmod −RtaodFaod + Vaod − Vaod0
Caod
− ψ(Vaod)
]
+ PvcRtaod
Rcrb +Rtaod
(46)
Paod = ABPshift (47)
Psap =
Vsap − Vsap0
Csap
− ψ(Vsap) (48)
Psa,a = Kc log10
[
Vsa − Vsa0
Do
+ 1
]
(49)
Psa,p = Kp1e
τp(Vsa−Vsa0) +Kp2(Vsa − Vsa0)2 (50)
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Psa = fvasoPsa,a + (1− fvaso)Psa,p (51)
Psc =
Vsc − V sc0
Csc
− ψ(Vsc) (52)
Psv = −Kv log10
[
Vmax,sv
Vsv
− 0.99
]
(53)
Rsa = Kr
(
e4fvaso +
V 2sa,max
V 2sa
)
+Rsa0 (54)
Rvc = KR
V 2max,vc
V 2vc
+R0 (55)
Fcrb =
MAPmod − Pvc
Rcrb
(56)
Fsap =
Psap − Psa
Rsap
(57)
Fsa =
Psa − Psc
Rsa
(58)
Fsc =
Psc − Psv
Rsc
(59)
Fsv =
Psv − Pvc
Rsv
(60)
Fvc =
Pvc − Pra
Rvc
(61)
dVaop
dt
=
Paop − Vaop − Vaop0
Caop
Rtaop
(62)
dVaod
dt
= AOFmod − Faod − Fcrb (63)
dVsa
dt
= Fsap − Fsa (64)
dVsap
dt
= Faod − Fsap (65)
dVsc
dt
= Fsa − Fsc (66)
dVsv
dt
= Fsc − Fsv (67)
dVvc
dt
= Fsv + Fcrb − Fvc (68)
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dAOFmod
dt
= (MAPmeas −MAPmod)Kcomap
60
(69)
dFrv,sm
dt
=
Frv − Frv,sm
τco
(70)
dFaod
dt
=
MAPmod − FaodRaod − Psap
Laod
(71)
dPpaop
dt
=
Flv − dVaop
dt
− Faop − Fcorepi
Ccorepi
(72)
dMAPmeas
dt
=
ABPshift −MAPmeas
τMAP
(73)
dCOmea
dt
=
PAFmeas − COmea
τco
(74)
dABPfol
dt
=
ABPshift −ABPfol
τABP
(75)
A.3.3 Pulmonary circulation
Ppap =

Ppap1 =
RtpapPrv −RrvFpapRtpap +
(
Rrv
Vpap − Vpap0
Cpap
− ψ(Vpap)
)
Rtpap +Rrv
Prv > Ppap1
Ppap2 =
−RrvFpapRtpap +
(
Rrv
Vpap − Vpap0
Cpap
− ψ(Vpap)
)
Rrv
Prv ≤ Ppap1
(76)
Ppad = FpapRtpad − FpadRtpad + Vpad − Vpad0
Cpad
− ψ(Vpad) (77)
Vp,i =
Vp,i − Vp,i,0
Cp,i
− ψ(Vp,i) (78)
Fps =
Ppa − Ppv
Rps
(79)
Fpa =
Ppa − Ppc
Rpa
(80)
Fpc =
Ppc − Ppv
Rpc
(81)
Fpv =
Ppv − Ppa
Rpv
(82)
dFpap
dt
=
Ppap − Ppad − FpapRpap
Lpap
(83)
dFpad
dt
=
Ppad − Ppa − FpadRpad
Lpad
(84)
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dVpad
dt
= Fpap − Fpad (85)
dVpap
dt
= Frv − Fpap (86)
dVpa
dt
= Fpad − Fps − Fpa (87)
dVpc
dt
= Fpa − Fpc (88)
dVpv
dt
= Fpc + Fps − Fpv (89)
A.3.4 Coronary circulation
Pcorepi = Paop (90)
Pcorintra =
Vcorintra − Vcorintra0
Ccorintra
− ψ(V) (91)
Pcorcap =
Vcorcap − Vcorcap0
Ccorcap
− ψ(Vcorcap) (92)
Pcorvn =
Vcorvn − Vcorvn0
Ccorvn
− ψ(Vcorvn) (93)
Pim =
⌊
Plv
2
⌋
(94)
Pcorintrac = Pcorintra + Pim (95)
Pcorcapc = Pcorcap + Pim (96)
Pcorvnc = Pcorvn (97)
Fcorepi =
Pcorepi − Pcorintrac
Rcorepi
(98)
Fcorintra =
Pcorintrac − Pcorcapc
Rcorintra
(99)
Fcorcap =
Pcorcapc − Pcorvnc
Rcorcap
(100)
Fcorvn =
Pcorvnc − Pra
Rcorvn
(101)
dVcorepi
dt
= Flv − dVvaop
dt
− Faop − Fcorepi (102)
25
A PREPRINT - JUNE 12, 2020
dVcorintra
dt
= Fcorepi − Fcorintra (103)
dVcorcap
dt
= Fcorintra − Fcorcap (104)
dVcorvn
dt
= Fcorcap − Fcorvn (105)
A.3.5 Baroreceptor
bvaso = 1− avaso (106)
fvaso = avaso +
bvaso
eτvaso(Nvaso−No,vaso)) + 1
(107)
Nbr,t =
dNbr
dt
(108)
dNbr,t
dt
=
−(a2 + a)Nbr,t −Nbr +K
(
ABPshift + a1
dABPfol
dt
)
a2a
(109)
dNi
dt
=

−Ni +KiNbr(t− li)
Ti
t− tHB(0) > li
0 t− tHB(0) ≤ li
(110)
A.3.6 Blood volumes
Vcorcic = Vcorepi + Vcorintra + Vcorcap + Vcorvn (111)
Vheart = Vra + Vrv + Vla + Vlv + Vcorcic (112)
Vsysart = Vaop + Vaod + Vsap + Vsa (113)
Vsysven = Vsv + Vvc (114)
Vpulart = Vpap + Vpad + Vpa (115)
TBV = Vheart + Vsysart + Vsc + Vsysven + Vpulart + Vpc + Vpv (116)
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A.4 Parameters of the renin-angiotensin system
Table 3: Pharmacokinetic parameters
Parameter NRF IRF Units Sources Description
ka 1.907 1.645 h−1 [46, 79] absorption rate constant
ke 1.33× 10−1 3.45× 10−2 h−1 [46, 79] elimination rate constant
V/F 7.09× 104 1.07× 105 mL [46, 79] ratio of the volume of distribution to the fraction of the drug absorbed
Table 4: Pharmacodynamic parameters
Parameter Value Units Sources Description
kAGT 2.27× 106 nmol/L/h [48, 14] constant production rate of AGT
kRenin 6.44× 104 h−1 [46, 14] ANG-I production rate due to renin
kNEP 0.583 h
−1 [48, 14] NEP-catalyzed conversion rate from ANG-I to ANG-(1-7)
kAT2 25.1 h
−1 [48, 14] rate parameter for binding of ANG II to AT1R
kAPA 43.6 h
−1 [48, 14] APA-catalyzed conversion rate from ANG-II to ANG-III
hAGT 10.0 h [49, 48, 14] AGT half-life degradation rate
hRenin 0.250 h [48, 14] renin half-life degradation rate
hANGI 1.72× 10−4 h [49, 48, 14] ANG-I half-life degradation rate
hANGII 5× 10−3 h [49, 48, 14] ANG-II half-life degradation rate
[Drug]50 2.20 ng/mL [79, 48, 14] drug concentration yielding 50% inhibition
m 0.99 - [79, 48, 14] degree of sigmoidicity of the Hill function
aRenin 5.47× 10−4 L/mmol/h [48, 14] slope of the linear dependence of renin from glucose
bRenin 6.16× 10−11 h−1 [48, 14] intercept of the linear dependence of renin from glucose
aACE 0.889 L/mmol/h [48, 14] slope of the linear dependence of ACE from glucose
bACE 163 h
−1 [48, 14] intercept of the linear dependence of ACE from glucose
aAT1 2.55 L/mmol/h [48, 14] slope of the linear dependence of AT1R from glucose
bAT1 464 h
−1 [48, 14] intercept of the linear dependence of AT1R from glucose
kf,sys 6.25× 10−2 h−1 [46, 14] ANG-II feedback parameter on renin
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Table 4 continued from previous page
Parameter Value Units Sources Description
fsys 0.397 nmol/L [46, 14] ANG-II feedback parameter on renin
[AGT ]0 1.70× 107 nmol/L [48, 14] AGT initial concentration
[Renin]0 2.06× 10−4 nmol/L [46, 14] renin initial concentration
[ANGI]0 271 nmol/L [48, 14] ANG-I initial concentration
[ANGII]0 21.0 nmol/L [48, 14] ANG-II initial concentration
[ANGII]0,sysNRF 1.65× 10−2 nmol/L [46, 14] systemic ANG-II initial concentration for normal renal individuals
[ANGII]0,sysIRF 2.05× 10−2 nmol/L [46, 14] systemic ANG-II initial concentration for impaired renal individuals
hANG17 0.5 h [49] ANG-17 half-life degradation rate
[ANG17]0 9.858 nmol/L [80] ANG-17 initial concentration
hAT1R 0.2 h [49] AT1R half-life degradation rate
[AT1R]0 16.2 nmol/L [80] AT1R initial concentration
hAT2R 0.2 h [49] AT2R half-life degradation rate
[AT2R]0 5.4 nmol/L [80] AT2R initial concentration
kACE2,0 0.385 h
−1 [48, 14] ACE-catalyzed conversion rate from ANG-II to ANG-(1-7)
sI 0.1 h
−1L/nmol - severity of SARS-CoV-2 infection
eAI 0.347 - - efficiency of anti-inflammatory pathways
A.5 Parameters of the diabetic model
Table 5: Diabetic parameters
Parameter Value Units Sources Description
k 432 d−1 [81] combined insulin uptake at the liver, kidneys, and insulin receptors
α 20000 mg2dl−2 [82] glucose concentration yielding 50% of insulin secretion
σ 43.2 µU ml−1d−1 [83, 82, 81] maximal rate secretion of insulin by β cells
R0 864 mg dl
−1d−1 [83, 84] net rate of production at zero glucose
R1 1 ml dl
−1 g−1 - net rate of glucose increase due to meals
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Table 5 continued from previous page
Parameter Value Units Sources Description
R2 0.1 ml dl
−1 kcal−1 - net rate of glucose consumption due to workouts
EG0 0.44 d
−1 [83, 84] total glucose effectiveness at zero insulin
SI (normal) 1.62 ml µU−1d−1 [84] normal insulin sensitivity
SI (diabetic) 0.52 ml µU−1d−1 [84] diabetic insulin sensitivity
r0 0.06 d
−1 [83, 85, 84] death rate at zero glucose
r1 0.00084 mg
−1dl d−1 [83, 85, 84] I-order coefficient for β cell replication
r2 0.0000024 mg
−2dl d−1 [83, 85, 84] II-order coefficient for β cell replication
i0 87 - [13] insulin resistance self-inhibition rate
m 2 - [13] insulin resistance progression rate due to pro-inflammatory cytokines
q 0.017 ml/µU [13] insulin resistance progression rate due to insulin concentration
I0 13.59 µU/ml [13] initial insulin concentration
G0 100 ml/dl [13] initial glucose concentration
βf,0 407.73 - [13] number of functional β-cells
IR,0 0.359 - - initial insulin resistance
A.6 Parameters of the stiffness model
Table 6: Stiffness parameters
Parameter Value Units Sources Description
kSARS 0.15 h inflammation rate due to SARS-CoV-2
kD 0.001 mL/ng inflammation rate due to ACEi surplus
kG 0.1 L/mmol inflammation rate due to glucose surplus
keff (healthy state) 0.035 - anti-inflammatory response rate
keff (during infection) 0.693 - anti-inflammatory response rate
β1 0.006 - compliance reduction rate due to ageing
β0 1.2 - compliance reduction intercept due to ageing
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Table 6 continued from previous page
Parameter Value Units Description
IR0 0.385 - inflammatory response initial condition
A.7 Parameters of the open-loop circulatory model
Parameter Value Units Description
Ts1v 0.349 sec Scaler to set ventricular systolic fraction of heart cycle
Ts1a 0.2 sec Scaler to set atrial systolic fraction of heart cycle
Ts2 1 hz Unit balance scalar for Tsa and Tsv functions
offv 0.0263 sec Parameter to match model and measured end-diastolic ABP
V lvd0 71.816 ml Unstressed end-diastolic left ventricle volume
V lvs0 23.699 ml Unstressed end-systolic left ventricle volume
V rvd0 102.881 ml Unstressed end-diastolic right ventricle volume
V rvs0 53.498 ml Unstressed end-systolic right ventricle volume
V lad0 70 ml Unstressed end-diastolic left atrium volume
V las0 40 ml Unstressed end-systolic left atrium volume
V rad0 60 ml Unstressed end-diastolic right atrium volume
V ras0 53 ml Unstressed end-systolic right atrium volume
Rra 0.001 mmHg s ml−1 Tricuspid valve resistance
Rla 0.001 mmHg s ml−2 Mitral valve resistance
Rlv 0.0001 mmHg s ml−3 Aortic valve resistance
Rrv 0.0001 mmHg s ml−4 Pulmonary valve resistance
PRint 0.12 sec Difference in atrial, venticular activation times
KElv 1 Scaling factor for maximum left ventricular elastance
KErv 1 Scaling factor for maximum right ventricular elastance
Emaxlv1 5.4 mmHg/ml Maximum elastance of first left ventricle component
30
A
P
R
E
P
R
IN
T
-
JU
N
E
12,2020
Table 7 continued from previous page
Parameter Value Units Description
Eminlv 0.09 mmHg/ml Minimum elastance of first left ventricle component
Emaxrv1 0.53 mmHg/ml Maximum elastance of first right ventricle component
Eminrv 0.0343 mmHg/ml Minimum elastance of first right ventricle component
EDV LV 125.993 ml
EDV RV 175.865 ml
Emaxra 0.13 mmHg/ml Maximum elastance right ventricle
Eminra 0.085 mmHg/ml Minimum elastance left ventricle
Emaxla 0.299 mmHg/ml Maximum elastance right ventricle
Eminla 0.185 mmHg/ml Minimum elastance left ventricle
KCOMAP 3 L/mmHg/min2
Raop 0.0001 mmHg sec ml−1 Proximal aortic resistance
Rtaop 0.02 mmHg sec ml−1 Transmural proximal aortic resistance
Rcrb 6.8284 mmHg sec ml−1 Cerebral circulation resistance
Raod 0.0129 mmHg sec ml−1 Distal aortic resistance
Rtaod 1 mmHg sec ml−1 Transmural distal aortic resistance
Rsap 0.003 mmHg sec ml−1 Systemic arteriolar resistance
Rsc 0.155 mmHg sec ml−1 Systemic capillaries resistance
Rsv 0.138 mmHg sec ml−1 Systemic veins resistance
Caop 0.263 ml mmHg−1 Aortic proximal compliance
Caod 0.639 ml mmHg−1 Aortic distal compliance
Csap 1.482 ml mmHg−1 Systemic arterioles compliance
Csc 5.767 ml mmHg−1 Systemic capillaries compliance
V aop0 9.520 ml Proximal aorta unstressed volume
V aod0 23.11 ml Distal aorta unstressed volume
V sap0 52.94 ml Systemic arteries unstressed volume
V sc0 71.02 ml Systemic capillaries unstressed volume
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Table 7 continued from previous page
Parameter Value Units Description
Laop 1e− 05 mmHg sec2 ml−1 Proximal aorta intertance
Laod 2e− 05 mmHg sec2 ml−1 Distal aorta inertance
Kc 497.785 mmHg Active vasomotor tone scaling parameter for systemic arterial pressure
Do 50 ml Active vasomotor tone volume parameter for systemic arterial pressure
V sa0 485.762 ml Minimal volume of systemic arteries
V sa_max 577.711 ml Maximal luminal volume of systemic arteries
Kp1 0.0299 mmHg Passive vasomotor tone scaling parameter for systemic arterial pressure
Kp2 0.05 mmHg ml−2 Passive vasomotor tone scaling parameter for systemic arterial pressure
Kr 0.01 mmHg sec ml−1 Pressure scaling constant for systemic arterial resistance
Rsa0 0.581 mmHg sec/ml Offset parameter for systemic arteriolar resistance
tau_p 0.1 ml−1 Passive vasomotor tone constant for systemic arterial pressure
Ksv 0.74 Scaling factor used to optimize systemic venous pressure-volume relationship
Kv1 30.21 mmHg Scaling factor for systemic venous pressure
V max_sv 3379.55 ml Maximal volume of lumped systemic veins
D2 −5 mmHg Offsetting constant for partially collapsed Vena cava pressure
K1 0.046 mmHg ml−1 Scaling factor for Vena cava PV relationship
K2 0.374 mmHg Scaling factor for partially collapsed Vena cava pressure
KR 0.001 mmHg sec ml−1 Scaling factor for Vena cava resistance
R0 0.025 mmHg sec ml−1 Vena cava resistance offset parameter
V vc0 129.649 ml Unstressed volume of Vena cava
V max_vc 350.53 ml Maximum volume of Vena cava
V min_vc 50.01 ml Minimum volume of Vena cava
tauCO 15 sec Cardiac output equation time constant
Kxp 2 mmHg P-V curve shaping parameter
Kxv 8 ml P-V curve shaping parameter
Kxv1 1 ml P-V curve shaping parameter
32
A
P
R
E
P
R
IN
T
-
JU
N
E
12,2020
Table 7 continued from previous page
Parameter Value Units Description
Kxp1 1 mmHg P-V curve shaping parameter
tauMAP 2 sec Time constant for mean arterial pressure ODE
tauABP 0.001 sec Time constant for ABP follower
Rtpap 0.1 mmHg sec ml−1 Proximal pulmonary arterial transmural resistance
Rtpad 0.2 mmHg sec ml−1 Distal pulmonary arterial transmural resistance
Rpap 0.0001 mmHg sec ml−1 Proximal pulmonary resistance
Rpad 0.0299 mmHg sec ml−1 Distal proximal pulmonary resistance
Rps 4.333 mmHg sec ml−1 Pulmonary shunt resistance
Rpa 0.057 mmHg sec ml−1 Pulmonary arterioles resistance
Rpc 0.032 mmHg sec ml−1 Pulmonary capillaries resistance
Rpv 0.0001 mmHg sec ml−1 Pulmonary veins resistance
Cpap 1.445 ml mmHg−1 Proximal pulmonary arterial compliance
Cpad 2.531 ml mmHg−1 Distal pulmonary arterial compliance
Cpa 3.102 ml mmHg−1 Pulmonary arterioles compliance
Cpc 9.117 ml mmHg−1 Pulmonary capillaries compliance
Cpv 52.267 ml mmHg−1 Pulmonary veins compliance
V pap0 9.81 ml Proximal pulmonary artery unstressed volume
V pad0 17.16 ml Distal pulmonary artery unstressed volume
V pa0 17.16 ml Small pulmonary arteries unstressed volume
V pc0 29.42 ml Pulmonary capillaries unstressed volume
V pv0 29.597 ml Pulmonary veins unstressed volume
Lpap 0.00018 mmHg sec2 ml−1 Proximal arterial inertance
Lpad 0.00019 mmHg sec2 ml−1 Distal pulmonary artery inertance
Rcorepi 5.285 s ml−1mmHg Proximal epicardial arteries resistance
Rcorintra 10.147 s ml−1mmHg Distal epicardial arteries resistance
Rcorcap 4.228 s ml−1mmHg Coronary capillaries resistance
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Table 7 continued from previous page
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Rcorvn 1.48 s ml−1mmHg Small coronary veins resistance
Ccorepi 0.074 ml/mmHg Compliance of proximal epicardial arteries
Ccorintra 0.134 ml/mmHg Compliance of distal epicardial arteries
Ccorcap 0.94 ml/mmHg Compliance of coronary capillaries
Ccorvn 2.45 ml/mmHg Compliance of small coronary veins
V corepi0 2.69 ml Epicardial arteries unstressed volume
V corintra0 2.685 ml Intramyocardial arteries unstressed volume
V corcap0 2.523 ml Coronary capillaries unstressed volume
V corvn0 2.493 ml Coronary veins unstressed volume
a 0.001 sec Time constant for baroreceptor firing rate
a1 0.036 sec Time constant for baroreceptor firing rate
a2 0.0018 sec Time constant for baroreceptor firing rate
K 0.991 sec−1 mmHg−1 Baroreceptor gain (used to account for units)
K_con 1 CNS gain for contractility control
T_con 10 sec CNS time parameter for contractility control
l_con 3 sec CNS time delay for contractility control
a_con 0.299 Time constant for efferent contractility firing
b_con 0.699 Time constant for efferent sympathetic contractility firing
tau_con 0.04 sec Time parameter for efferent sympathetic contractility firing
No_con 110 sec−1 Frequency parameter for efferent sympathetic contractility firing
K_vaso 1 CNS gain for vasomotor tone control
T_vaso 6 sec CNS time parameter for vasomotor tone control
l_vaso 3 sec CNS time delay for vasomotor tone control
a_vaso −0.466 Time constant for efferent vasomotor tone firing
tau_vaso 0.04 sec Time parameter for efferent vasomotor tone firing
No_vaso 110 sec−1 Frequency parameter for efferent vasomotor tone firing
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amin −2.806 Contractility control offset
bmin 0.699 Contractility control offset
Ka 5 Contractility control scaling factor
Kb 0.5 Contractility control scaling factor
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